Finch Therapeutics Group, Inc. (FNCH)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
FNCH Insider Trading Activity
FNCH Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $21,246 | 1 | 100 |
Related Transactions
| SMISEK JEFFERY A | director | 0 | $0 | 1 | $21,246 | $-21,246 |
About Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Insider Activity of Finch Therapeutics Group, Inc.
Over the last 12 months, insiders at Finch Therapeutics Group, Inc. have bought $0 and sold $21,246 worth of Finch Therapeutics Group, Inc. stock.
On average, over the past 5 years, insiders at Finch Therapeutics Group, Inc. have bought $10.47M and sold $12,820 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,010 shares for transaction amount of $1,353 was made by Graf Susan E (director) on 2023‑06‑09.
List of Insider Buy and Sell Transactions, Finch Therapeutics Group, Inc.
| 2024-03-28 | Sale | SMISEK JEFFERY A | director | 8,242 0.5089% | $2.58 | $21,246 | +328.85% | |
| 2023-11-22 | Sale | SMISEK JEFFERY A | director | 1,470 0.0901% | $3.64 | $5,351 | -24.59% | |
| 2023-06-09 | Graf Susan E | director | 5,010 0.0003% | $0.27 | $1,353 | -54.64% | ||
| 2023-02-21 | Sale | Blaustein Marc | Chief Operating Officer | 4,619 0.0097% | $0.38 | $1,755 | -42.69% | |
| 2022-10-21 | Sale | Blaustein Marc | Chief Operating Officer | 3,636 0.0078% | $1.39 | $5,054 | -72.59% | |
| 2022-10-21 | Sale | Vittiglio Joseph | Chief Business & Legal Officer | 3,636 0.0078% | $1.39 | $5,054 | -72.59% | |
| 2021-12-20 | Haft Nicholas | director | 63,850 0.1713% | $10.18 | $649,993 | -73.92% | ||
| 2021-03-23 | Crestovo Investor LLC | 735,294 5.3498% | $17.00 | $12.5M | -19.16% | |||
| 2021-03-23 | SMISEK JEFFERY A | director | 88,235 0.642% | $17.00 | $1.5M | -19.16% | ||
| 2021-03-23 | Haft Nicholas | director | 882,351 6.4197% | $17.00 | $15M | -19.16% | ||
| 2021-03-23 | FERRANTE DOMENIC J | director | 102,941 0.749% | $17.00 | $1.75M | -19.16% |
Insider Historical Profitability
| SMISEK JEFFERY A | director | 0 0% | $0 | 1 | 2 | <0.0001% |
| Crestovo Investor LLC | 12641441 787.2559% | $178.24M | 1 | 0 | <0.0001% | |
| Haft Nicholas | director | 4056907 252.6472% | $57.2M | 2 | 0 | <0.0001% |
| FERRANTE DOMENIC J | director | 636195 39.6196% | $8.97M | 1 | 0 | <0.0001% |
| Vittiglio Joseph | Chief Business & Legal Officer | 31364 1.9532% | $442,232.40 | 0 | 1 | |
| Blaustein Marc | Chief Operating Officer | 27995 1.7434% | $394,729.50 | 0 | 2 | |
| Graf Susan E | director | 5010 0.312% | $70,641.00 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$6,204,522 | 45 | 1.91% | $20.02M | |
$550,024 | 37 | -2.68% | $20.31M | |
$23,895,365 | 34 | -37.28% | $28.81M | |
$1,363,112 | 33 | 15.03% | $21.03M | |
$1,295,471 | 17 | 21.79% | $26.63M | |
$79,536,861 | 15 | -6.81% | $21.3M | |
$25,487,383 | 15 | -4.37% | $21.17M | |
$39,336,371 | 14 | -17.87% | $27.45M | |
$474,020 | 10 | 23.32% | $20.67M | |
$20,715,938 | 10 | -42.51% | $26.47M | |
$38,613,178 | 10 | 5.24% | $24.77M | |
$5,574,954 | 8 | -0.97% | $30.58M | |
Finch Therapeutics Group, Inc. (FNCH) | $31,401,303 | 6 | -34.20% | $22.64M |
$40,324 | 6 | 31.81% | $22.58M | |
$25,999,992 | 4 | 13.36% | $21.67M | |
$1,184,658 | 4 | -22.17% | $25.13M | |
$5,030,159 | 2 | -23.30% | $27.64M | |
$30,190 | 1 | -42.39% | $20.19M | |
$500,000 | 1 | -22.94% | $25.07M |
FNCH Institutional Investors: Active Positions
| Increased Positions | <1 | company.increased | <1 | company.increased |
| Decreased Positions | <1 | company.decreased | <1 | company.decreased |
| New Positions | <1 | New | <1 | New |
| Sold Out Positions | <1 | Sold Out | <1 | Sold Out |
| Total Postitions | <1 | company.total | <1 | company.total |